The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee Osteoarthritis

被引:102
|
作者
Smith, Toby O. [19 ,20 ]
Hawker, Gillian A. [2 ,3 ]
Hunter, David J. [7 ,21 ,22 ,23 ]
March, Lyn M. [7 ,23 ,24 ]
Boers, Maarten [25 ]
Shea, Beverley J. [26 ]
Christensen, Robin [12 ,27 ]
Guillemin, Francis [28 ]
Terwee, Caroline B. [29 ]
Williamson, Paula R. [30 ]
Dodd, Susanna [31 ]
Roos, Ewa M. [32 ]
Loeser, Richard F. [33 ]
Schnitzer, Thomas J. [34 ]
Kloppenburg, Margreet [11 ,35 ]
Neogi, Tuhina [13 ,14 ]
Ladel, Christoph H. [16 ]
Kalsi, Gurdyal [36 ]
Kaiser, Ulrike [17 ]
Buttel, Thomas W. [7 ,8 ,37 ]
Ashford, Anne E. [9 ]
Mobasheri, Ali [38 ]
Arden, Nigel K. [39 ]
Tennant, Alan [18 ]
Hochberg, Marc C. [15 ,40 ]
de Wit, Maarten [10 ]
Tugwell, Peter [4 ,5 ,6 ]
Conaghan, Philip G. [1 ,41 ]
机构
[1] NIHR Leeds Biomed Res Ctr, Leeds, W Yorkshire, England
[2] Univ Toronto, Fac Med, Dept Med, Toronto, ON, Canada
[3] Univ Toronto, Inst Hlth Policy Management & Evaluat, Dalla Lana Sch Publ Hlth Univ, Toronto, ON, Canada
[4] Univ Ottawa, Dept Med, Div Rheurnatol, Fac Med, Ottawa, ON, Canada
[5] Univ Ottawa, Sch Epidemiol & Publ Hlth, Fac Med, Ottawa, ON, Canada
[6] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada
[7] Royal North Shore Hosp, St Leonards, NSW, Australia
[8] Inner West Psychol, Sydney, NSW, Australia
[9] Univ New South Wales, Sch Biol Earth & Environm Sci, Sydney, NSW, Australia
[10] Univ Amsterdam, Med Ctr, Dept Med Humanities, Amsterdam Publ Hlth, Amsterdam, Netherlands
[11] Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands
[12] Odense Univ Hosp, Dept Rheumatol, Odense, Denmark
[13] Boston Univ, Sch Med, Sect Clin Epidemiol, Boston, MA 02118 USA
[14] Boston Univ, Sch Med, Sect Rheumatol, Boston, MA 02118 USA
[15] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Div Gerontol, Baltimore, MD 21201 USA
[16] Merck KGaA, Merck Biopharma, Darmstadt, Germany
[17] Univ Hosp Carl Gustav Carus, Univ Pain Ctr, Dresden, Germany
[18] Univ Lucerne, Fac Humanities & Social Sci, Luzern, Switzerland
[19] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Rehabil, Oxford, England
[20] Joint Radcliffe Hosp, NIHR Oxford Biomed Res Ctr, Oxford, England
[21] Inst Bone & Joint Res, Rheumatol, St Leonards, NSW, Australia
[22] Inst Bone & Joint Res, Med, St Leonards, NSW, Australia
[23] Univ Sydney, Sch Med, Florance & Cope Professorial Dept Rheumatol, Sydney, NSW, Australia
[24] Inst Bone & Joint Res, Rheumatol & Musculosketal Epidemiol Med, St Leonards, NSW, Australia
[25] Univ Amsterdam, Dept Epidemiol & Biostat, Clin Epidemiol, Med Ctr, Amsterdam, Netherlands
[26] Ottawa Hosp Res Inst, Ottawa, ON, Canada
[27] Odense Univ Hosp, Musculoskeletal Stat Unit, Biostat & Clin Epidemiol, Bispebjerg & Frederiksberg Hosp,Parker Inst, Odense, Denmark
[28] Univ Lorraine, Epidemiol & Publ Hlth, APEMAC, Nancy, France
[29] Univ Amsterdam, Med Ctr, Dept Epidemiol & Biostat, Clinimetr,Locat VUmc, Amsterdam, Netherlands
[30] Univ Liverpool, Inst Translat Med, Med Stat, Liverpool, Merseyside, England
[31] Univ Liverpool, Biostat, Inst Translat Med, Liverpool, Merseyside, England
[32] Univ Southern Denmark, Ctr Muscle & Joint Hlth, Dept Sports Sci & Clin Biomech, Res Unit, Odense, Denmark
[33] Univ N Carolina, Thurston Arthrit Res Ctr, Div Rheumatol Allergy & Immunol, Med, Chapel Hill, NC 27515 USA
[34] Northwestern Univ, Sch Med, Dept Phys Med & Rehabil, Phys Med & Rehabil,Anesthesiol & Med Rheumatol, Chicago, IL USA
[35] Leiden Univ, Med Ctr, Dept Rheumatol, Rheumatol, Leiden, Netherlands
[36] TissueGene Inc, Clin Dev & Regulatory & Med Affairs, Rockville, MD USA
[37] Inst Bone & Joint Res, St Leonards, NSW, Australia
[38] Univ Surrey, Fac Hlth & Med Sci, Musculoskeletal Physiol, Guildford, Surrey, England
[39] Univ Oxford, Rheumat Dis, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England
[40] Univ Maryland, Dept Med, Div Rheumatol & Clin Immunol, Epidemiol & Publ Hlth,Sch Med, Baltimore, MD 21201 USA
[41] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Musculoskeletal Med, Leeds, W Yorkshire, England
关键词
OSTEOARTHRITIS; HIP JOINT; KNEE JOINT; OMERACT; OUTCOME MEASURE; CLINICAL TRIALS; OUTCOME DOMAINS; CHRONIC PAIN;
D O I
10.3899/jrheum.181194
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To update the 1997 OMERACT-OARSI (Outcome Measures in Rheumatology-Osteoarthritis Research Society International) core domain set for clinical trials in hip and/or knee osteoarthritis (OA). Methods. An initial review of the COMET database of core outcome sets (COS) was undertaken to identify all domains reported in previous COS including individuals with hip and/or knee OA. These were presented during 5 patient and health professionals/researcher meetings in 3 continents (Europe, Australasia, North America). A 3-round international Delphi survey was then undertaken among patients, healthcare professionals, researchers, and industry representatives to gain consensus on key domains to be included in a core domain set for hip and/or knee OA. Findings were presented and discussed in small groups at OMERACT 2018, where consensus was obtained in the final plenary. Results. Four previous COS were identified. Using these, and the patient and health professionals/researcher meetings, 50 potential domains formed the Delphi survey. There were 426 individuals from 25 different countries who contributed to the Delphi exercise. OMERACT 2018 delegates (n = 129) voted on candidate domains. Six domains gained agreement as mandatory to be measured and reported in all hip and/or knee OA clinical trials: pain, physical function, quality of life, and patient's global assessment of the target joint, in addition to the mandated core domain of adverse events including mortality. Joint structure was agreed as mandatory in specific circumstances, i.e., depending on the intervention. Conclusion. The updated core domain set for hip and/or knee OA has been agreed upon. Work will commence to determine which outcome measurement instrument should be recommended to cover each core domain.
引用
收藏
页码:981 / 989
页数:9
相关论文
共 50 条
  • [21] OARSI Clinical Trials Recommendations: Design and conduct of clinical trials for hip osteoarthritis
    Lane, N. E.
    Hochberg, M. C.
    Nevitt, M. C.
    Simon, L. S.
    Nelson, A. E.
    Doherty, M.
    Herontin, Y.
    Flechsenhar, K.
    OSTEOARTHRITIS AND CARTILAGE, 2015, 23 (05) : 761 - 771
  • [22] OMERACT/OARSI initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis
    Gossec, Laure
    Hawker, Gillian
    Davis, Aileen M.
    Maillefert, Jean Francis
    Lohmander, L. Stefan
    Altman, Roy
    Cibere, Jolanda
    Conaghan, Philip G.
    Hochberg, Marc C.
    Jordan, Joanne M.
    Katz, Jeffrey N.
    March, Lyn
    Mahomed, Nizar
    Pavelka, Karel
    Roos, Ewa M.
    Suarez-Almazor, Maria E.
    Zanoli, Gustavo
    Dougados, Maxime
    JOURNAL OF RHEUMATOLOGY, 2007, 34 (06) : 1432 - 1435
  • [23] Long-term efficacy of lumiracoxib in osteoarthritis demonstrated using the OMERACT-OARSI criteria
    Ouellet, JP
    Zacher, J
    Moore, A
    Lee, A
    Sloan, VS
    OSTEOARTHRITIS AND CARTILAGE, 2004, 12 : S84 - S85
  • [24] Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III
    Bellamy, N
    Kirwan, J
    Boers, M
    Brooks, P
    Strand, V
    Tugwell, P
    Altman, R
    Brandt, K
    Dougados, M
    Lequesne, M
    JOURNAL OF RHEUMATOLOGY, 1997, 24 (04) : 799 - 802
  • [25] The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica
    Mackie, Sarah L.
    Twohig, Helen
    Neill, Lorna M.
    Harrison, Eileen
    Shea, Beverley
    Black, Rachel J.
    Kermani, Tanaz A.
    Merkel, Peter A.
    Mallen, Christian D.
    Buttgereit, Frank
    Mukhtyar, Chetan
    Simon, Lee S.
    Hill, Catherine L.
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (10) : 1515 - 1521
  • [26] Lumiracoxib 100 mg once daily is effective in treating osteoarthritis as assessed by OMERACT-OARSI criteria
    Sheldon, E
    Beaulieu, A
    Paster, Z
    Dutta, D
    Yu, S
    Sloan, VS
    OSTEOARTHRITIS AND CARTILAGE, 2004, 12 : S140 - S141
  • [27] OARSI Clinical Trials Recommendations: Design, conduct, and reporting of clinical trials for knee osteoarthritis
    McAlindon, T. E.
    Driban, J. B.
    Henrotin, Y.
    Hunter, D. J.
    Jiang, G-L
    Skou, S. T.
    Wang, S.
    Schnitzer, T.
    OSTEOARTHRITIS AND CARTILAGE, 2015, 23 (05) : 747 - 760
  • [28] Clinical response to intra-articular injections of hylan G-F 20 in symptomatic hip osteoarthritis: the OMERACT-OARSI criteria applied to the results of a pilot study
    Conrozier, Thierry
    Bertin, Philippe
    Bailleul, Francois
    Mathieu, Pierre
    Charlot, Jacques
    Vignon, Eric
    Treves, Richard
    Chevalier, Xavier
    JOINT BONE SPINE, 2006, 73 (06) : 705 - 709
  • [29] OARSI/OMERACT Criteria of Being Considered a Candidate for Total Joint Replacement in Knee/Hip Osteoarthritis as an Endpoint in Clinical Trials Evaluating Potential Disease Modifying Osteoarthritic Drugs
    Dougados, Maxime
    Hawker, Gillian
    Lohmander, Stefan
    Davis, Aileen M.
    Dieppe, Paul
    Maillefert, Jean-Francis
    Gossec, Laure
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (09) : 2097 - 2099
  • [30] Post-hoc analysis of a head-to-head hyaluronic acid comparison in knee osteoarthritis using the 2004 OMERACT-OARSI responder criteria
    Onel, Erol
    Kolsun, Kathleen
    Kauffman, Jeffrey I.
    CLINICAL DRUG INVESTIGATION, 2008, 28 (01) : 37 - 45